FCGR3A and asthma: However, the expression level of CD16 on CD14++CD16+ intermediate subset monocytes was significantly lower in patients with moderate (p = 0.006) and severe (p = 0.004) asthma and there was also a significant decrease (p = 0.005) in CD16 expression on the non-classical CD14+CD16++ monocyte subset in patients with severe asthma compared to healthy controls (Fig. 3b).